Coronavirus disease (COVID-19) is an infectious disease caused by the coronavirus SARS-CoV-2. Here we have collected APR news related to the COVID-19 pandemic, vaccination efforts and emerging treatments.
Thursday, October 07, 2021
The submission includes recent results from the Phase 3 ENSEMBLE 2 study that found a booster of the Johnson & Johnson COVID-19 vaccine given 56 days after the primary dose provided 94 percent ...
read more
Thursday, October 07, 2021
Pfizer and BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion on the administration of the companies’ ...
read more
Tuesday, October 05, 2021
GSK announced it has signed an agreement with the Government of Canada to supply 10,000 doses of Sotrovimab for injection, a COVID-19 monoclonal antibody therapy developed by GSK and Vir Biotechnology...
read more
Thursday, September 30, 2021
REGEN-COV significantly reduced viral load in patients hospitalized with COVID-19 who entered the trial without having mounted their own antibody response (seronegative) and required low-flow or no ...
read more
Thursday, September 30, 2021
The Companies announced positive topline results from the pivotal trial on September 20, 2021. In the trial, which included 2,268 participants 5 to 12
read more
Thursday, September 30, 2021
The CDC Foundation is announcing the launch of its new Vaccine Resource Hub—an online platform that will provide access to hundreds of free and accurate resources about COVID-19 and influenza ...
read more
Thursday, September 30, 2021
CVS Health announced that, following approval from the Centers for Disease Control and Prevention (CDC) based on guidance from the organization's Advisory Committee on Immunization Practices (ACIP), ...
read more
Thursday, September 23, 2021
Pfizer and BioNTech announced that the FDA has authorized for emergency use a booster dose of the Pfizer-BioNTech COVID-19 Vaccine for individuals 65 years of age and older, individuals 18 through 64 ...
read more
Thursday, September 23, 2021
Eli Lilly and Company announced a Joint Procurement Agreement with the European Commission (EC) to supply up to 220,000 doses of bamlanivimab and etesevimab for the treatment of confirmed COVID-19 in ...
read more
Thursday, September 23, 2021
SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human polyclonal antibodies without ...
read more
Thursday, September 23, 2021
Valneva, a specialty vaccine company, announced that it has commenced recruitment of adolescents in its pivotal Phase 3 Clinical Trial (VLA2001-301, “Cov-Compare”) for its inactivated COVID-19 vaccine...
read more
Wednesday, September 22, 2021
Pfizer and BioNTech announced results from a Phase 2/3 trial showing a favorable safety profile and robust neutralizing antibody responses in children 5 to 11 years of age using a two-dose regimen of ...
read more
Wednesday, September 22, 2021
Pfizer and BioNTech that the FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the FDA grant Emergency Use Authorization (EUA) for a booster dose ...
read more
Wednesday, September 22, 2021
Pfizer and BioNTech announced plans to expand their agreement with the U.S. government by providing an additional 500 million doses of the companies’ COVID-19 vaccine at a not-for-profit price for ...
read more
Monday, September 20, 2021
The FDA revised the emergency use authorization (EUA) for bamlanivimab and etesevimab, administered together, to include emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults ...
read more